117 related articles for article (PubMed ID: 15342421)
1. High frequency of functionally active Melan-a-specific T cells in a patient with progressive immunoproteasome-deficient melanoma.
Meidenbauer N; Zippelius A; Pittet MJ; Laumer M; Vogl S; Heymann J; Rehli M; Seliger B; Schwarz S; Le Gal FA; Dietrich PY; Andreesen R; Romero P; Mackensen A
Cancer Res; 2004 Sep; 64(17):6319-26. PubMed ID: 15342421
[TBL] [Abstract][Full Text] [Related]
2. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
Ayyoub M; Rimoldi D; Guillaume P; Romero P; Cerottini JC; Valmori D; Speiser D
Cancer Res; 2003 Sep; 63(17):5601-6. PubMed ID: 14500401
[TBL] [Abstract][Full Text] [Related]
3. Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy.
Oelke M; Moehrle U; Chen JL; Behringer D; Cerundolo V; Lindemann A; Mackensen A
Clin Cancer Res; 2000 May; 6(5):1997-2005. PubMed ID: 10815925
[TBL] [Abstract][Full Text] [Related]
4. A direct comparison of cytolytic T-lymphocyte responses to Melan-A peptides in vitro: differential immunogenicity of Melan-A27-35 and Melan-A26-35.
Chen Q; Jackson H; Cebon J; Gibbs P; Davis ID; Trapani JA
Melanoma Res; 2000 Feb; 10(1):16-25. PubMed ID: 10711636
[TBL] [Abstract][Full Text] [Related]
5. Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues.
Carrabba MG; Castelli C; Maeurer MJ; Squarcina P; Cova A; Pilla L; Renkvist N; Parmiani G; Rivoltini L
Cancer Res; 2003 Apr; 63(7):1560-7. PubMed ID: 12670905
[TBL] [Abstract][Full Text] [Related]
6. Processing of tumor-associated antigen by the proteasomes of dendritic cells controls in vivo T-cell responses.
Chapatte L; Ayyoub M; Morel S; Peitrequin AL; Lévy N; Servis C; Van den Eynde BJ; Valmori D; Lévy F
Cancer Res; 2006 May; 66(10):5461-8. PubMed ID: 16707475
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen.
Schütz A; Oertli D; Marti WR; Noppen C; Padovan E; Spagnoli GC; Heberer M; Zajac P
Cancer Gene Ther; 2001 Sep; 8(9):655-61. PubMed ID: 11593334
[TBL] [Abstract][Full Text] [Related]
8. Umbilical cord blood T cells respond against the Melan-A/MART-1 tumor antigen and exhibit reduced alloreactivity as compared with adult blood-derived T cells.
Merindol N; Grenier AJ; Caty M; Charrier E; Duval A; Duval M; Champagne MA; Soudeyns H
J Immunol; 2010 Jul; 185(2):856-66. PubMed ID: 20543110
[TBL] [Abstract][Full Text] [Related]
9. High avidity melanoma-reactive cytotoxic T lymphocytes are efficiently induced from peripheral blood lymphocytes on stimulation by peptide-pulsed melanoma cells.
Gervois N; Labarriere N; Le Guiner S; Pandolfino MC; Fonteneau JF; Guilloux Y; Diez E; Dreno B; Jotereau F
Clin Cancer Res; 2000 Apr; 6(4):1459-67. PubMed ID: 10778978
[TBL] [Abstract][Full Text] [Related]
10. Melanoma patients respond to a cytotoxic T lymphocyte-defined self-peptide with diverse and nonoverlapping T-cell receptor repertoires.
Dietrich PY; Walker PR; Quiquerez AL; Perrin G; Dutoit V; Liénard D; Guillaume P; Cerottini JC; Romero P; Valmori D
Cancer Res; 2001 Mar; 61(5):2047-54. PubMed ID: 11280765
[TBL] [Abstract][Full Text] [Related]
11. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
[TBL] [Abstract][Full Text] [Related]
12. Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1.
Ayyoub M; Zippelius A; Pittet MJ; Rimoldi D; Valmori D; Cerottini JC; Romero P; Lejeune F; Liénard D; Speiser DE
Clin Cancer Res; 2003 Feb; 9(2):669-77. PubMed ID: 12576434
[TBL] [Abstract][Full Text] [Related]
13. Human melanoma-specific, noncytolytic CD8+ T cells that can synthesize type I cytokine.
Chakraborty NG; Mukherji B
Cancer Res; 1998 Apr; 58(7):1363-6. PubMed ID: 9537230
[TBL] [Abstract][Full Text] [Related]
14. High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival.
Karanikas V; Colau D; Baurain JF; Chiari R; Thonnard J; Gutierrez-Roelens I; Goffinet C; Van Schaftingen EV; Weynants P; Boon T; Coulie PG
Cancer Res; 2001 May; 61(9):3718-24. PubMed ID: 11325844
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8(+) T cells with a memory phenotype.
Sensi M; Nicolini G; Zanon M; Colombo C; Molla A; Bersani I; Lupetti R; Parmiani G; Anichini A
Cancer Res; 2005 Jan; 65(2):632-40. PubMed ID: 15695408
[TBL] [Abstract][Full Text] [Related]
16. Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts.
Jandus C; Bioley G; Dojcinovic D; Derré L; Baitsch L; Wieckowski S; Rufer N; Kwok WW; Tiercy JM; Luescher IF; Speiser DE; Romero P
Cancer Res; 2009 Oct; 69(20):8085-93. PubMed ID: 19808957
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
18. Effector T cell analysis of melanoma tumor-infiltrating lymphocyte cultures using HLA-ABC semimatched melanoma cell lines.
Carlsson B; Sadeghi A; Bengtsson M; Wagenius G; Tötterman TH
J Immunother; 2008 Sep; 31(7):633-43. PubMed ID: 18600181
[TBL] [Abstract][Full Text] [Related]
19. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells.
Morel S; Lévy F; Burlet-Schiltz O; Brasseur F; Probst-Kepper M; Peitrequin AL; Monsarrat B; Van Velthoven R; Cerottini JC; Boon T; Gairin JE; Van den Eynde BJ
Immunity; 2000 Jan; 12(1):107-17. PubMed ID: 10661410
[TBL] [Abstract][Full Text] [Related]
20. A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes.
Schiavetti F; Thonnard J; Colau D; Boon T; Coulie PG
Cancer Res; 2002 Oct; 62(19):5510-6. PubMed ID: 12359761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
